This prospective multicenter longitudinal study aims to investigate the prevalence, pathogenesis, and prognosis of pulmonary hypertension in patients with end-stage renal disease undergoing chronic hemodialysis. The research seeks to identify specific clinical factors and biomarkers like angiopoietin-2 that contribute to the development of this condition, while evaluating the prognostic value of right ventricular function measured via TAPSE. Participants undergo a standardized screening echocardiogram the day after their intermediate dialysis session to determine the probability of pulmonary hypertension. Those identified as high-risk receive further diagnostic confirmation through right heart catheterization, respiratory function tests, and lung scans to clarify the underlying etiology. The protocol also evaluates the hemodynamic impact of high-flow arteriovenous fistulas and volume overload on pulmonary pressures. Clinical follow-up is conducted at baseline and subsequently at 6, 12, and 24 months to monitor patient outcomes and standardize therapeutic management according to established European guidelines.
Patients aged between 18 and 75 years
Patients on stable extracorporeal hemodialysis for at least 6 months
Dialysis frequency of two or three times per week
Ability to provide written informed consent
WHO functional class IV
Presence of valvular or congenital heart disease
Acute infections within the month preceding the cardiological evaluation
The study population consists of adult patients (18-75 years old) with end-stage renal disease who have been receiving stable extracorporeal hemodialysis for at least six months at participating multicenter dialysis units.
Cohort
Prospective
Not listed
Prevalence of pulmonary hypertension and its subtypes in patients undergoing chronic hemodialysis
Click on the lead sponsor to view all of their trials.
